Skip to main content
padlock icon - secure page this page is secure

Open Access Preface

Download Article:
(PDF 88.7 kb)
Dear Readers and Contributors,

It is a real pleasure at the beginning of this year to provide you with some information on the current status of Endocrine Metabolic Immune Disorders-Drug Targets (EMID-DT). In the last year, EMID-DT took a very impressive step forward due to the following circumstances. On the one hand, the journal has offered the opportunity to the scientific community to submit original articles in addition to review articles. This has increased the number of submissions as well as the dissemination of novel findings about the endocrine immune axis and its modulation with drugs or natural products. Also in the case of original paper submissions we have applied very strict criteria of acceptance through a peer-reviewing in order to publish top articles. On the other hand, according to SCImago Journal and Country Rank, the cites per doc (2 years) were equivalent to 2.85 Impact Factor (IF) in 2010. The journal has been scheduled to receive its conventional IF in 2013 and, therefore, these figures seem to be predictive of a quite high IF in the immediate future.

Also in view of these concepts, the journal must maintain and improve its current status via high standard publications in the form of special issues, single reviews and original articles.

Finally, I wish to thank all the editorial board members and external reviewers who have contributed to the progress of EMID-DT. Also, I wish to acknowledge the strenuous work of the Editorial Office collaborators who are constantly contributing to the success of the journal and timely interact with contributors and readers. I would also want to express my appreciation to Dr. Matthew Honan for his great support and wise advices in all these years....
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Publication date: March 1, 2012

More about this publication?
  • This journal is devoted to timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Topics related to the neuroendocrine-immune axis are given special emphasis in view of the growing interest in stress-related, inflammatory, autoimmune, and degenerative disorders.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more